CommercialPrior AuthHigh impact
Provider Update - Redirection of Care & Holiday Closures
Blue Cross Blue Shield of Wyoming·WY · Oncology, Hematology, Rheumatology +2 more·Prior Authorization
Effective date
Jan 1, 2022
We identified it
Jun 19, 2026
Summary
Blue Cross Blue Shield of Wyoming is implementing a redirection of care program that requires certain high-cost infusion medications to be administered in the most cost-effective setting (infusion centers, provider offices, or home health) rather than hospital outpatient departments. This affects prior authorization for 10 specific medications including Remicade, Keytruda, and Herceptin.
Action Required
Immediately: Billing team must verify authorization letters for patients receiving Neulasta, Remicade, Avastin, Rituxab, Herceptin, Keytruda, Ocrevus, Opdivo, Somatuline, or Soliris note any redirection requirements. Contact BCBSWY Redirection of Care Team at 307-823-6095 for questions about affected patients. Update prior authorization workflows to check for site-of-care restrictions on these medications. Plan for reduced availability December 24 and December 31 due to BCBSWY holiday closures.